In contrast to traditional drugs that are derived from chemicals, biologics are made from living cells.
These trends indicate that consumers and payers could soon see substantial savings from increased utilization of biosimilar drugs.
State biosimilar substitution laws may be standing in the way.
Many of these arguments mirror concerns previously raised about traditional generic drug substitution that ultimately proved groundless.
The FDA and the US Federal Trade Commission have echoed these concerns.
The biosimilar market will be unable to provide such benefits if interchangeable biosimilar substitution is unnecessarily constrained.
Virginia Voters Are Concerned About Drug Affordability
Prescription drug affordability is a concern for many Virginia voters.
They call for a Prescription Drug Affordability Board to address the issue.
